Search company, investor...

Founded Year



Grant - IX | Alive

Total Raised


Last Raised

$1.4M | 1 yr ago

About Aural Analytics

Aural Analytics is a company focused on clinical-grade speech analytics in the healthcare sector. The company offers a suite of mobile-first solutions that extract clinically relevant measures from speech, providing non-invasive and actionable insights into neurological health. Their primary market is the healthcare industry, specifically in the area of neurological disease monitoring. It was founded in 2015 and is based in Scottsdale, Arizona.

Headquarters Location

1475 N. Scottsdale Rd.

Scottsdale, Arizona, 85257,

United States


Aural Analytics's Products & Differentiators

    Speech Vitals

    Our product combines our mobile app, task-metric battery, and objective outcome measures.


Research containing Aural Analytics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Aural Analytics in 2 CB Insights research briefs, most recently on Apr 6, 2021.

Expert Collections containing Aural Analytics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aural Analytics is included in 3 Expert Collections, including Digital Health.


Digital Health

10,714 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.


Digital Health 50

150 items

2022's cohort of the most promising digital health startups transforming the healthcare industry. Winners were chosen based on several factors, including data submitted by the companies, proprietary Mosaic scores, company business models and momentum in the market.

Aural Analytics Patents

Aural Analytics has filed 4 patents.

The 3 most popular patent topics include:

  • medical ethics
  • analgesics
  • dosage forms
patents chart

Application Date

Grant Date


Related Topics



Respiratory therapy, Machine learning, Respiratory physiology, Inflammations, Syndromes


Application Date


Grant Date


Related Topics

Respiratory therapy, Machine learning, Respiratory physiology, Inflammations, Syndromes



Latest Aural Analytics News

FDA Grants Breakthrough Device Designation to Aural Analytics for Speech Analytics Software to Be Used in Treatment of ALS

Mar 30, 2023

News FDA Grants Breakthrough Device Designation to Aural Analytics for Speech Analytics Software to Be Used in Treatment of ALS Speech Vitals - ALS is a software application used in the collection and analysis of speech recordings to assist neurologists in the monitoring of amyotrophic lateral sclerosis (ALS) in adults in both clinic and home environments Speech Vitals - ALS is a software application used in the collection and analysis of speech recordings. (Credit: ThisisEngineering RAEng on Unsplash) Aural Analytics, Inc., a leader in clinical-grade speech analytics, today announced that its Speech Vitals – ALS technology has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA). Speech Vitals – ALS is a software application used in the collection and analysis of speech recordings to assist neurologists in the monitoring of amyotrophic lateral sclerosis (ALS) in adults in both clinic and home environments. The Breakthrough Device Designation is currently held by fewer than 800 devices, of which less than 140 are intended for neurological disorders and even fewer are used for ALS treatment. Medical devices receive breakthrough designation from the FDA when they provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and healthcare providers with timely access to groundbreaking technologies by expediting the approval process. “Achieving breakthrough designation for Speech Vitals – ALS is explicit validation that the FDA sees the potential in the Speech Vitals platform to provide for more effective management of this devastating disease,” said Jeremy Moore, Director of Quality Assurance & Regulatory Affairs at Aural Analytics. “We look forward to working closely with the agency to continue to develop our platform to achieve De Novo clearance to get it into the hands of the physicians and patients that need it the most.” Speech Vitals collects just a few minutes of speech samples from patients via app-based tasks that measure speaking rate, articulatory precision, phonatory duration and many other metrics. These metrics serve the purpose of assessing speech-motor conditions. Speech as a vital sign reduces the patient burden, as it is collected through a user-friendly app that can be deployed on any device in-clinic or at home. Speech Vitals is SDK-ready and can be embedded into provider and healthcare system applications, ensuring seamless integration into a clinician’s everyday practice. Aural Analytics intends to pursue additional indications using Speech Vitals – ALS, to include diagnosis. Once Speech Vitals achieves regulatory clearance, the technology will be applied to additional conditions that impact speech, such as Parkinson’s Disease. Source: Company Press Release

Aural Analytics Frequently Asked Questions (FAQ)

  • When was Aural Analytics founded?

    Aural Analytics was founded in 2015.

  • Where is Aural Analytics's headquarters?

    Aural Analytics's headquarters is located at 1475 N. Scottsdale Rd., Scottsdale.

  • What is Aural Analytics's latest funding round?

    Aural Analytics's latest funding round is Grant - IX.

  • How much did Aural Analytics raise?

    Aural Analytics raised a total of $9.95M.

  • Who are the investors of Aural Analytics?

    Investors of Aural Analytics include National Institutes of Health, National Science Foundation, Tamarisc, Marc Abramowitz, Morningside Ventures and 8 more.

  • Who are Aural Analytics's competitors?

    Competitors of Aural Analytics include Winterlight Labs and 6 more.

  • What products does Aural Analytics offer?

    Aural Analytics's products include Speech Vitals.


Compare Aural Analytics to Competitors

Ellipsis Health Logo
Ellipsis Health

Ellipsis Health develops artificial intelligence (AI) generated vocal biomarker technology. It helps in identifying, assessing, and monitoring mental health with a short voice sample. Its technology determines the severity of anxiety and depression. Ellipsis Health was founded in 2017 and is based in San Francisco, California.


Kintsugi develops and offers mental healthcare infrastructure software solutions using novel voice biomarker software to streamline access to care. It detects signs of clinical depression and anxiety using machine learning and voice biomarkers. It was founded in 2019 and is based in Berkeley, California.

Sonde Health Logo
Sonde Health

Sonde Health is a health technology company that provides voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. The platform analyzes vocal features that reflect changes in a user's voice caused by changing physiology of their body due to symptoms of the disease. The company was founded in 2015 and is based in Boston, Massachusetts.

Modality.AI Logo

Modality.AI detects health conditions using conversational artificial intelligence (AI). It monitors and assesses neurological and psychiatric conditions, both in clinical settings and remotely. The company primarily serves the healthcare industry, particularly in the areas of neurological and psychiatric care. It was founded in 2018 and is based in San Francisco, California.

Vocalis Health Logo
Vocalis Health

Vocalis Health is a vocal biomarker company using voice to detect, diagnose, and monitor patient health. Its technology leverages machine learning (ML) and deep learning (DL) techniques to analyze voice recordings for insights regarding various health conditions via a mobile application and web browser. The company was founded in 2019 and is based in Newton, Massachusetts.

Deliberate AI Logo
Deliberate AI

Deliberate AI is a company focused on the application of artificial intelligence in the healthcare sector, specifically in the assessment of psychiatric and neurological health. The company's main service involves the extraction of features from audio-visual signals and other modalities to compute clinically significant biomarkers and predictive models for psychiatric and neurologic disorders. These services primarily cater to the life sciences industry, including biopharma and medical device companies. It was founded in 2020 and is based in New York, New York.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.